Abstract
The etiology of seizures in the Neurosurgical/Neurological Intensive Care Unit (NICU) can be categorized as emanating from either primary brain pathology, at either macro- or microscopic level, or from physiological derangements of critical care illness such as toxic or metabolic abnormalities. Particular etiologies at risk for seizures include ischemic or hemorrhagic stroke and traumatic brain injury. The use of prophylactic antiepileptic drug administration remains controversial in many situations, with most of the larger studies having used older antiepileptic drugs prophylactically. If seizures do occur, patients are typically treated with parenteral antiepileptic drugs. The duration of treatment is unknown in most situations, but it should be individualized depending on acute and monophasic injury versus chronic process. Late seizures, which occur after the first 2 weeks from the insult, have a more ominous risk for subsequent epilepsy and should be treated for extended periods of time or indefinitely. Electrolyte and glucose abnormalities and medications at high or low levels, when corrected, usually lead to seizure control. This review discusses the risk for seizures with commonly encountered types of brain injuries in the NICU and ends by examining the treatment algorithms for simple seizures and status epilepticus and the role newer antiepileptics may potentially play.
Keywords: Antiepileptic drugs, neurosurgical intensive care unit, trauma, brain tumors, stroke, seizures.
Current Pharmaceutical Design
Title:Antiepileptic Drugs in the Neurosurgical Intensive Care
Volume: 23 Issue: 42
Author(s): Panayiotis N. Varelas*Mathew Jones
Affiliation:
- Neurosurgery, Henry Ford Hospital, Detroit MI, 48203,United States
Keywords: Antiepileptic drugs, neurosurgical intensive care unit, trauma, brain tumors, stroke, seizures.
Abstract: The etiology of seizures in the Neurosurgical/Neurological Intensive Care Unit (NICU) can be categorized as emanating from either primary brain pathology, at either macro- or microscopic level, or from physiological derangements of critical care illness such as toxic or metabolic abnormalities. Particular etiologies at risk for seizures include ischemic or hemorrhagic stroke and traumatic brain injury. The use of prophylactic antiepileptic drug administration remains controversial in many situations, with most of the larger studies having used older antiepileptic drugs prophylactically. If seizures do occur, patients are typically treated with parenteral antiepileptic drugs. The duration of treatment is unknown in most situations, but it should be individualized depending on acute and monophasic injury versus chronic process. Late seizures, which occur after the first 2 weeks from the insult, have a more ominous risk for subsequent epilepsy and should be treated for extended periods of time or indefinitely. Electrolyte and glucose abnormalities and medications at high or low levels, when corrected, usually lead to seizure control. This review discusses the risk for seizures with commonly encountered types of brain injuries in the NICU and ends by examining the treatment algorithms for simple seizures and status epilepticus and the role newer antiepileptics may potentially play.
Export Options
About this article
Cite this article as:
Varelas N. Panayiotis *, Jones Mathew, Antiepileptic Drugs in the Neurosurgical Intensive Care, Current Pharmaceutical Design 2017; 23 (42) . https://dx.doi.org/10.2174/1381612823666171030150437
DOI https://dx.doi.org/10.2174/1381612823666171030150437 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach
Current Pharmaceutical Biotechnology The Role of Neuroimaging in Our Understanding of the Suicidal Brain
CNS & Neurological Disorders - Drug Targets Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer’s Disease Therapy: Advances in Chemical and Biological Research
Current Medicinal Chemistry Neuromodulation of Hippocampal Synaptic Plasticity, Learning, and Memory by Noradrenaline
Central Nervous System Agents in Medicinal Chemistry Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder
Current Drug Safety Nanotechnological Advances in the Treatment of Epilepsy
CNS & Neurological Disorders - Drug Targets Pharmacokinetics and Metabolic Drug Interactions
Current Clinical Pharmacology The Role of Topiramate and Other Anticonvulsants in the Treatment of Alcohol Dependence: A Clinical Review
CNS & Neurological Disorders - Drug Targets Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels
Current Neuropharmacology Increased Epileptiform EEG Activity and Decreased Seizure Threshold in Arctic APP Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research The Urokinase Receptor Interactome
Current Pharmaceutical Design Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review
Recent Patents on Anti-Cancer Drug Discovery Modulation of the Basal Ganglia by Metabotropic Glutamate Receptors: Potential for Novel Therapeutics
Current Drug Targets - CNS & Neurological Disorders Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Editorial (Hot Topic: Organic Solute Transporters and Diseases: Potential Therapeutic Targets)
Current Molecular Pharmacology The Adverse Effects of Smoking on Health Outcomes in Bipolar Disorder: A Review and Synthesis of Biological Mechanisms
Current Molecular Medicine HIV-1 Tat-Induced Changes in Synaptically-Driven Network Activity Adapt During Prolonged Exposure
Current HIV Research Cell-based Treatment of Cerebral Palsy: Still a Long Way Ahead
Current Stem Cell Research & Therapy Myopathic Involvement and Mitochondrial Pathology in Kennedy Disease and in Other Motor Neuron Diseases
Current Molecular Medicine Exploiting High-Throughput Ion Channel Screening Technologies in Integrated Drug Discovery
Current Pharmaceutical Design